DIA Conference to Feature Sessions on Drug Labeling, Pandemic Flu

The Drug Information Association's 45th Annual Meeting, taking place June 21-25 in San Diego, will be the latest installment in the biopharmaceutical industry's largest and longest running global, multidisciplinary conference featuring sessions and preconference tutorials on issues affecting drug discovery and development. Included in this year's lineup are two timely sessions reflecting the state of today's global biopharmaceutical environment.

On June 22, from 1:30-3 p.m., the public policy/law track will feature a special session titled "Labeling Risk: Practical Approaches after Wyeth v. Levine, which will explore practical approaches pharmaceutical companies should consider when disseminating risk information to minimize failure-to-warn liability and to maximize the possibility such liability is preempted. DIA notes that in March 2009, The Wall Street Journal reported that the Supreme Court ruling in Wyeth stated that pharmaceutical companies are not necessarily shielded from failure-to-warn product liability lawsuits in state courts when the U.S. FDA has determined that approved labeling appropriately explains risk information.

"We will delve deep into the legal benefits of preemptions, describe regulatory and documentation strategies that maximize the availability of preemption in failure-to-warn lawsuits, and identify effective risk communication strategies," says Session Chair Patrick C O'Brien, JD, PharmD, a partner at Burke O'Neil LLC. Speakers for this session will include John B Moriarty, JD, senior vice president of Elan Pharmaceuticals; Sandra A. Milligan, JD, M.D., executive director of Amgen Inc.; and Mary K. Pendergast, JD, LLM, president of Pendergast Consulting.

Another timely session of note at this year's conference, featured in the biotechnology track, is "Regulatory Methods to Facilitate the Approval of Biological Products to Address Pandemic Influenza," which will also take place June 22 from 1:30-3 p.m. Incorporating descriptions of novel regulatory mechanisms for vaccine approval with a discussion of successful applications for pandemic influenza, the session will focus on industry approaches toward interactions with FDA, and the latest biochemical methods for the development of vaccines. Chaired by Richard M Lewis, Ph.D., CEO of Access BIO, the session's speakers will include Jean L Hu-Primmer, MS, program manager of the USFDA's Pandemic and Emerging Threat Preparedness Division; John Purves, Ph.D., head of the European Medicines Agency's Quality of Medicines Sector; and Ozzie Berger, senior director and head of Influenza Vaccines at GlaxoSmithKline's U.S. Regulatory Affairs, Biologicals Division.

DIA serves more than 30,000 professionals involved in the biopharmaceutical industry and regulatory affairs worldwide. Through its domestic and international meetings, training courses, workshops, and webinars, the association provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Led by its volunteer-based board of directors and executive management team, DIA is headquartered in Horsham, Pa., and has offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; and Beijing, China. For more conference information and registration, visit www.diahome.org/ or the conference Web site.

Download Center

  • OSHA Recordkeeping Guide

    In case you missed it, OSHA recently initiated an enforcement program to identify employers who fail to electronically submit Form 300A recordkeeping data to the agency. When it comes to OSHA recordkeeping, there are always questions regarding the requirements and ins and outs. This guide is here to help! We’ll explain reporting, recording, and online reporting requirements in detail.

  • Incident Investigations Guide

    If your organization has experienced an incident resulting in a fatality, injury, illness, environmental exposure, property damage, or even a quality issue, it’s important to perform an incident investigation to determine how this happened and learn what you can do to prevent similar incidents from happening in the future. In this guide, we’ll walk you through the steps of performing an incident investigation.

  • Lone Worker Guide

    Lone workers exist in every industry and include individuals such as contractors, self-employed people, and those who work off-site or outside normal hours. These employees are at increased risk for unaddressed workplace accidents or emergencies, inadequate rest and breaks, physical violence, and more. To learn more about lone worker risks and solutions, download this informative guide.

  • Job Hazard Analysis Guide

    This guide includes details on how to conduct a thorough Job Hazard Analysis, and it's based directly on an OSHA publication for conducting JHAs. Download the guide to learn how to identify potential hazards associated with each task of a job and set controls to mitigate hazard risks.

  • The Basics of Incident Investigations Webinar

    Without a proper incident investigation, it becomes difficult to take preventative measures and implement corrective actions. Watch this on-demand webinar for a step-by-step process of a basic incident investigation, how to document your incident investigation findings and analyze incident data, and more. 

  • Vector Solutions

OH&S Digital Edition

  • OHS Magazine Digital Edition - October 2022

    October 2022

    Featuring:

    • FACILITY SAFETY
      Here's Why Constant Bending Can Be Troublesome
    • INDUSTRIAL HYGIENE
      How Artificial Intelligence in Revolutionizing Jobs
    • PPE: RESPIRATORY PROTECTION
      Choosing the Right Respiratory Protection
    • WINTER HAZARDS
      Managing Cold Stress with the Proper PPE
    View This Issue